Mangrove Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Mangrove Partners’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Hold	9,916	–	–	0.08%	123
2026 Q1	$916K	Buy	+9,916	New	+$933K	0.07%	118

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mangrove Partners's MIRM Position: Q2 2026 in Review

Mangrove Partners held its Mirum Pharmaceuticals (MIRM) position steady in Q2 2026 at 9,916 shares worth $1.16M. The position accounts for 0.08% of the portfolio, ranked #123.

Mangrove Partners first reported a position in MIRM in Q1 2026 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Mangrove Partners held 9,916 shares of Mirum Pharmaceuticals worth $1.16M as of Q2 2026.
Mangrove Partners left its Mirum Pharmaceuticals share count unchanged in Q2 2026.
Mirum Pharmaceuticals made up 0.08% of Mangrove Partners's portfolio in Q2 2026, its #123 holding.
Mangrove Partners first reported a position in Mirum Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.